Literature DB >> 27622058

Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Frederik C Henrich1, Katrin Singer2, Kerstin Poller1, Luise Bernhardt1, Carolin D Strobl1, Katharina Limm3, Axel P Ritter4, Eva Gottfried5, Simon Völkl1, Benedikt Jacobs6, Katrin Peter5, Dimitrios Mougiakakos1, Katja Dettmer4, Peter J Oefner4, Anja-Katrin Bosserhoff3, Marina P Kreutz5, Michael Aigner1, Andreas Mackensen1.   

Abstract

The immunosuppressive tumor microenvironment represents one of the main obstacles for immunotherapy of cancer. The tumor milieu is among others shaped by tumor metabolites such as 5'-deoxy-5'-methylthioadenosine (MTA). Increased intratumoral MTA levels result from a lack of the MTA-catabolizing enzyme methylthioadenosine phosphorylase (MTAP) in tumor cells and are found in various tumor entities. Here, we demonstrate that MTA suppresses proliferation, activation, differentiation, and effector function of antigen-specific T cells without eliciting cell death. Conversely, if MTA is added to highly activated T cells, MTA exerts cytotoxic effects on T cells. We identified the Akt pathway, a critical signal pathway for T cell activation, as a target of MTA, while, for example, p38 remained unaffected. Next, we provide evidence that MTA exerts its immunosuppressive effects by interfering with protein methylation in T cells. To confirm the relevance of the suppressive effects of exogenously added MTA on human T cells, we used an MTAP-deficient tumor cell-line that was stably transfected with the MTAP-coding sequence. We observed that T cells stimulated with MTAP-transfected tumor cells revealed a higher proliferative capacity compared to T cells stimulated with Mock-transfected cells. In conclusion, our findings reveal a novel immune evasion strategy of human tumor cells that could be of interest for therapeutic targeting.

Entities:  

Keywords:  Antitumor immune response; MTA; MTAP; T cells; cell signaling; immunosuppression; protein methylation; tumor metabolism

Year:  2016        PMID: 27622058      PMCID: PMC5007975          DOI: 10.1080/2162402X.2016.1184802

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  81 in total

Review 1.  Protein arginine methylation in lymphocyte signaling.

Authors:  Fabien Blanchet; Brandon T Schurter; Oreste Acuto
Journal:  Curr Opin Immunol       Date:  2006-04-17       Impact factor: 7.486

2.  Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways.

Authors:  Maria Nyåkern; Alessandra Cappellini; Irina Mantovani; Alberto M Martelli
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

3.  S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells.

Authors:  Eduardo Ansorena; Elena R García-Trevijano; Maria L Martínez-Chantar; Zong-Zhi Huang; Lixin Chen; José M Mato; Maria Iraburu; Shelly C Lu; Matías A Avila
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

4.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

5.  Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA).

Authors:  Georgi Kirovski; Axel P Stevens; Barbara Czech; Katja Dettmer; Thomas S Weiss; Peter Wild; Arndt Hartmann; Anja K Bosserhoff; Peter J Oefner; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2011-01-28       Impact factor: 4.307

Review 6.  Tumor metabolism as modulator of immune response and tumor progression.

Authors:  Eva Gottfried; Marina Kreutz; Andreas Mackensen
Journal:  Semin Cancer Biol       Date:  2012-03-03       Impact factor: 15.707

Review 7.  Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.

Authors:  Joseph R Bertino; William R Waud; William B Parker; Martin Lubin
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

8.  Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.

Authors:  K R Jerome; N Domenech; O J Finn
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

9.  Anergic T cells are metabolically anergic.

Authors:  Yan Zheng; Greg M Delgoffe; Christian F Meyer; Waipan Chan; Jonathan D Powell
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

Review 10.  The tumor microenvironment and its role in promoting tumor growth.

Authors:  T L Whiteside
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

View more
  21 in total

1.  PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.

Authors:  Lindsay M Webb; Stephanie A Amici; Kyle A Jablonski; Himanshu Savardekar; Amanda R Panfil; Linsen Li; Wei Zhou; Kevin Peine; Vrajesh Karkhanis; Eric M Bachelder; Kristy M Ainslie; Patrick L Green; Chenglong Li; Robert A Baiocchi; Mireia Guerau-de-Arellano
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 2.  Emerging Role for Methylation in Multiple Sclerosis: Beyond DNA.

Authors:  Lindsay M Webb; Mireia Guerau-de-Arellano
Journal:  Trends Mol Med       Date:  2017-05-04       Impact factor: 11.951

Review 3.  Understanding the Intersections between Metabolism and Cancer Biology.

Authors:  Matthew G Vander Heiden; Ralph J DeBerardinis
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

4.  Primed mesenchymal stem cells package exosomes with metabolites associated with immunomodulation.

Authors:  Megan R Showalter; Benjamin Wancewicz; Oliver Fiehn; Joehleen A Archard; Shannon Clayton; Joseph Wagner; Peter Deng; Julian Halmai; Kyle D Fink; Gerhard Bauer; Brian Fury; Nicholas H Perotti; Michelle Apperson; Janelle Butters; Peter Belafsky; Gregory Farwell; Maggie Kuhn; Jan A Nolta; Johnathon D Anderson
Journal:  Biochem Biophys Res Commun       Date:  2019-03-26       Impact factor: 3.575

5.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

Review 6.  Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy.

Authors:  Weijing Dai; Jianguo Zhang; Siqi Li; Fajian He; Qiao Liu; Jun Gong; Zetian Yang; Yan Gong; Fang Tang; Zhihao Wang; Conghua Xie
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

Review 7.  Protein Arginine Methyltransferase 5 in T Lymphocyte Biology.

Authors:  Shouvonik Sengupta; Austin Kennemer; Kristin Patrick; Philip Tsichlis; Mireia Guerau-de-Arellano
Journal:  Trends Immunol       Date:  2020-09-02       Impact factor: 19.709

Review 8.  Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment.

Authors:  Kathrin Renner; Katrin Singer; Gudrun E Koehl; Edward K Geissler; Katrin Peter; Peter J Siska; Marina Kreutz
Journal:  Front Immunol       Date:  2017-03-08       Impact factor: 7.561

9.  PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.

Authors:  Marcella Barbarino; Daniele Cesari; Maria Bottaro; Luca Luzzi; Asadoor Namagerdi; Franca Maria Bertolino; Cristiana Bellan; Fabrizio Proietti; Pasquale Somma; Mariacarolina Micheli; Maria Margherita de Santi; Raffaella Guazzo; Luciano Mutti; Luigi Pirtoli; Piero Paladini; Paola Indovina; Antonio Giordano
Journal:  J Cell Mol Med       Date:  2020-04-17       Impact factor: 5.310

Review 10.  On point in primary CNS lymphoma.

Authors:  Mazie Tsang; Joseph Cleveland; James L Rubenstein
Journal:  Hematol Oncol       Date:  2020-07-03       Impact factor: 5.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.